Related Topics:
Facility ID: 01432PHRMC25PAT
Facility Name and Address: VERANOVA L.P. 25 PATTON RD DEVENS, MA 01434 Parent Company: VERANOVA BIDCO L.P. Industry: Pharmaceutical Preparation Manufacturing (325412) Chemical: Methyl tert-butyl ether Reports: View TRI Facility profile report for this facility View TRI Form R submissions by this facility |
|
*You can navigate within the map with your mouse. |
Production Related Waste Management for Selected Chemical
lchemid=0001634044
Chart Options1: |
Waste Management Comparison -
Display facility comparison report for this industry and chemical
Display facility comparison report for this parent company
Pollution Prevention Activities for Selected Chemical
Reporting Year | Section 8.10: Newly Implemented Source Reduction Activity | Section 8.10: Methods to Identify Activity | Section 8.11: Optional Pollution Prevention Information* |
---|---|---|---|
2019 |
Barriers: B3-Barriers to P2 B3 - Concern that product quality may decline as a result of source reduction.
|
Barriers to P2: B3 - Concern that product quality may decline as a result of source reduction. - JM IS A CONTRACT PHARMACEUTICAL MANUFACTURING AND RESEARCH FIRM WHICH MANUFACTURES PRODUCTS ON A BATCH BASISBY CLIENT. THE CLIENTS PROJECTS DICTATE THE CHEMICALS USED AND THE QUANTITIES. AS THESE PRODUCTS MAY BE IN FDAAPPROVAL PROCESS OR ALREADY FDA APPROVED JM HAS LITTLE OPPORTUNITY TO ENCOURAGE LESS HAZARDOUS CHEMICALSUBSTITUTIONS. WHEN POSSIBLE IN EARLY STAGES OF WORKING WITH NEW CLIENT, JM WILL OFFER TO OPTIMIZE PROCESS WHICHMAY RESULT IN LESS CHEMICALS USED OVERALL BY REDUCING NUMBER OF FILTRATIONS, WASHES, ETC. |
|
2018 |
Barriers: B3-Barriers to P2 B3 - Concern that product quality may decline as a result of source reduction.
|
Barriers to P2: B3 - Concern that product quality may decline as a result of source reduction. - JM IS A CONTRACT PHARMACEUTICAL MANUFACTURING AND RESEARCH FIRM WHICH MANUFACTURES PRODUCTS ON A BATCH BASISBY CLIENT. THE CLIENTS PROJECTS DICTATE THE CHEMICALS USED AND THE QUANTITIES. AS THESE PRODUCTS MAY BE IN FDAAPPROVAL PROCESS OR ALREADY FDA APPROVED JM HAS LITTLE OPPORTUNITY TO ENCOURAGE LESS HAZARDOUS CHEMICALSUBSTITUTIONS. WHEN POSSIBLE IN EARLY STAGES OF WORKING WITH NEW CLIENT, JM WILL OFFER TO OPTIMIZE PROCESS WHICHMAY RESULT IN LESS CHEMICALS USED OVERALL BY REDUCING NUMBER OF FILTRATIONS, WASHES, ETC. |
|
2017 |
Other Barriers to Source Reduction - JM IS A CONTRACT PHARMACEUTICAL MANUFACTURING AND RESEARCH FIRM WHICH MANUFACTURES PRODUCTS ON A BATCH BASIS BY CLIENT. THE CLIENTS PROJECTS DICTATE THE CHEMICALS USED AND THE QUANTITIES. AS THESE PRODUCTS MAY BE IN FDA APPROVAL PROCESS OR ALREADY FDA APPROVED JM HAS LITTLE OPPORTUNITY TO ENCOURAGE LESS HAZARDOUS CHEMICAL SUBSTITUTIONS. WHEN POSSIBLE IN EARLY STAGES OF WORKING WITH NEW CLIENT, JM WILL OFFER TO OPTIMIZE PROCESS WHICH MAY RESULT IN LESS CHEMICALS USED OVERALL BY REDUCING NUMBER OF FILTRATIONS, WASHES, ETC Other Environmental Practices: Energy Recovery - JM approved waste disposal facilities will seek energy recovery disposal options whenever possible. |
||
2013 |
Source Reduction:: W58: Other process modifications
|
Methods to Identify SR Opportunities: T11: Other
|
Source Reduction - When the process allows less solvents are used or solvents are reused. This is dependent on the project and the client. The operations team will review each project before stating to determine which steps might allow for less solvent use or solvent reuse within campaign. |
2012 |
Other Barriers to Source Reduction - The particular chemistry performed by the site in the production of client specific compounds requires use of certain solvents. Efforts are made to substitute less hazardous chemicals when possible but this is not feasible in most circumstances. |